Resveratrol Inhibits MMP3 and MMP9 Expression and Secretion by Suppressing TLR4/NF-κB/STAT3 Activation in Ox-LDL-Treated HUVECs

Figure 3

The TLR4 inhibitor CLI-095 abolishes the expression and secretion of MMP3 and MMP9 in ox-LDL- and LPS-treated HUVECs. The cells were treated with various concentrations of CLI-095 for 1 h, and ox-LDL (0.1 mg/ml) or LPS (5 μg/ml) was then added for 8 h. The expression of MMP3 and MMP9 was analyzed by Western blot. The secretion of MMP3 and MMP9 was measured by an ELISA kit. The column chart represents the density analysis from three independent experiments. (a, c, e) CLI-095 suppressed MMP3 and MMP9 expression that was induced by ox-LDL. (b, d, f) Resveratrol suppressed MMP3 and MMP9 expression that was induced by LPS. (g, i) CLI-095 reduced MMP3 secretion in ox-LDL- and LPS-treated HUVECs. (h, j) CLI-095 reduced MMP9 secretion in ox-LDL- and LPS-treated HUVECs. , , significant difference between non-ox-LDL-treated cells and ox-LDL-treated cells or between non-LPS-treated cells and LPS-treated cells; , , significant difference between non-resveratrol-treated cells and resveratrol-treated cells.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)